<DOC>
	<DOC>NCT00062478</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and efficacy ofKarenitecin (BNP1350) as a treatment of adults with brain tumors.</brief_summary>
	<brief_title>Study of Karenitecin (BNP1350) in Patients With Brain Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma. Evidence of measurable recurrent or residual primary CNS neoplasm. An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy. Hematocrit &gt; 29%, ANC &gt; 1,500, platelets &gt; 125,000 Serum creatinine &lt; 1.5 mg/dl, BUN &lt; 25 mg/dl, serum SGOT and bilirubin &lt; 1.5 times upper limit of normal Negative pregnancy test for female patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>